As a result of the acquisition’s close, Avedro’s common stock will now cease to trade on the Nasdaq.
American Society of Cataract and Refractive Surgery to Include Multiple Glaukos Technologies Presentations
4/11/18: Clinical trial results and personal experience data will be discussed to be discussed.
International Study Shows Two Glaukos iStent® Trabecular Micro-Bypass Stents and One Topical Medication Deliver Sustained IOP Reduction
April 13, 2017 Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that a study published in Clinical...